Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Arjun Datt Law, MBBS, MDDM, Mahadeo A. Sukhai, BSc, MSc, PhD, Mariam Thomas, PhD, Andrea Arruda, MSc., Narmin Ibrahimova, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Hassan Sibai, MD, Karen W.L. Yee, MD, Dwayne L. Barber, PhD, Tracy L. Stockley, PhD, Suzanne Kamel-Reid, PhD DABMG, FACMG, Andre C. Schuh, MD FRCPC

Blood (2016) 128 (22): 2886.

https://doi.org/10.1182/blood.V128.22.2886.2886

Published: 2016

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Blood (2016) 128 (22): 4263.

https://doi.org/10.1182/blood.V128.22.4263.4263

Published: 2016

Journal Articles

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Blood (2015) 126 (23): 3848.

https://doi.org/10.1182/blood.V126.23.3848.3848

Published: 2015

Journal Articles

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Dennis Dong Hwan Kim, MDPhD, Isabelle Bence-Bruckler, MD FRCPC, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Suzanne Kamel-Reid, PhD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 4554.

https://doi.org/10.1182/blood.V124.21.4554.4554

Published: 2014

Journal Articles

Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm

Signy Chow, MD FRCPC, Jacob M Pendergrast, MD FRCPC, Gorka Ochoa-Garay, Vikas Gupta, MD FRCP, FRCPath, Muhammad Ejaz Munir, MBBS, FRCS, Cuihong Wei, PhD FCCMG, Kenneth J Craddock, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Christine Cserti-Gazdewich, MD FRCPC

Blood (2014) 124 (21): 5105.

https://doi.org/10.1182/blood.V124.21.5105.5105

Published: 2014

Journal Articles

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

Uday Deotare, MD DM, Marwan Shaheen, MD, Joseph M. Brandwein, MD FRCPC, Bethany Gill, BSc, MMath, Suzanne Kamel-Reid, PhD DABMG, FACMG, Karen W.L. Yee, MDFRCPC, Anna Rydlewski, MD, Andrzej Lutynski, MD, Amr Rostom, MDCFPC, Aaron D Schimmer, MDPhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Andre C Schuh, MD FRCPC

Blood (2014) 124 (21): 3693.

https://doi.org/10.1182/blood.V124.21.3693.3693

Published: 2014

Journal Articles

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Mohamed Shanavas, MD, FRACP, FRCPA, Hans A. Messner, MD, PhD, Suzanne Kamel-Reid, PhD, Eshetu G Atenafu, MSc, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura Ellis, NP, MN, RN (EC), Jeffrey H. Lipton, MD, PhD

Blood (2013) 122 (21): 5501.

https://doi.org/10.1182/blood.V122.21.5501.5501

Published: 2013

Journal Articles

A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis

Blood (2012) 120 (21): 1586.

https://doi.org/10.1182/blood.V120.21.1586.1586

Published: 2012

Journal Articles

BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.

Dennis Dong Hwan Kim, MD, PhD, Hong Gi Lee, Suzanne Kamel-Reid, PhD, Jeffrey H. Lipton, MD, PhD

Blood (2012) 120 (21): 2777.

https://doi.org/10.1182/blood.V120.21.2777.2777

Published: 2012

Journal Articles

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Brian Leber, MD, Nelson Spector, MD, PhD, Francisco Cervantes, MD, PhD, Ricardo Pasquini, MD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Suzanne Kamel-Reid, PhD, Israel Bendit, MD, John Reynolds, PhD, Lisa Williams, Tomasz Szczudlo, Susan Branford, PhD

Blood (2011) 118 (21): 606.

https://doi.org/10.1182/blood.V118.21.606.606

Published: 2011

Journal Articles

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Jerald P. Radich, MD, Kenneth J. Kopecky, PhD, Suzanne Kamel-Reid, PhD, Wendy Stock, MD, Elisabeth Paietta, PhD, Martha Wadleigh, MD, Richard A. Larson, MD, Peter D. Emanuel, MD, Martin S. Tallman, MD, Jeffrey Lipton, MD, FRCPC, Stephen Couban, BSc, MD, Michael W. Deininger, MD, PhD, Frederick R. Appelbaum, MD, Brian J. Druker, MD

Blood (2010) 116 (21): LBA-6.

https://doi.org/10.1182/blood.V116.21.LBA-6.LBA-6

Published: 2010

Journal Articles

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Richard Ward, BSc, MRCP, FRCPath, Suzanne Kamel-Reid, PhD, FACMG, Wei Xu, PhD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Karen WL Yee, MD, Andre Schuh, MD, Vikas Gupta, MD, Joseph Brandwein, MD

Blood (2009) 114 (22): 1591.

https://doi.org/10.1182/blood.V114.22.1591.1591

Published: 2009

Journal Articles

Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.

Dong Hwan Kim, MD, PhD, Suzanne Kamel-Reid, PhD, FACMG, Hong Chang, MD, Robert Sutherland, Ph.D., Chul Won Jung, M.D./Ph.D., Hyeoung Joon Kim, MD, Je-Jung Lee, MD, PhD, Jeffrey H. Lipton, MD, PhD

Blood (2008) 112 (11): 933.

https://doi.org/10.1182/blood.V112.11.933.933

Published: 2008

Journal Articles

Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput Techniques

Rashmi S Goswami, MD, FRCPC, Nilva de Karla Cervigne, MSc, Patricia Pintor dos Reis, PhD, Mahadeo A Sukhai, PhD, John Kuruvilla, MD, FRCPC, Michael Crump, MD, FRCPC, Denis Bailey, MD, FRCPC, Suzanne Kamel-Reid, PhD, FACMG

Blood (2008) 112 (11): 2824.

https://doi.org/10.1182/blood.V112.11.2824.2824

Published: 2008

Journal Articles

Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.

Dong Hwan Kim, MD, PhD, Hee Kyung Ahn, M.D., Wei Xu, PhD, Suzanne Kamel-Reid, PhD, FACMG, Xiangdong Liu, Ph.D., Katherine Siminovitch, M.D./Ph.D., Jeffrey H. Lipton, MD, PhD

Blood (2008) 112 (11): 1110.

https://doi.org/10.1182/blood.V112.11.1110.1110

Published: 2008

Journal Articles

Systems Analysis Reveals Regulators of Apoptosis, Cell Cycle, Signal Transduction and Transcription as Novel Direct Targets of the Acute Promyelocytic Leukemia Fusion Protein NuMA-RAR α

Mahadeo A. Sukhai, BSc, MSc, Mariam Thomas, BSc, Yali Xuan, BSc, Patricia P. Reis, PhD, Rikki R. Bharadwaj, MSc, Suzanne Kamel-Reid, PhD

Blood (2006) 108 (11): 2247.

https://doi.org/10.1182/blood.V108.11.2247.2247

Published: 2006

Journal Articles

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Jamshid S. Khorashad, MD, Jeffrey H. Lipton, MD, David Marin, MD, Dragana Milojkovic, MD, Nicholas C.P. Cross, PhD, Nicholas Dibb, PhD, Junia V. Melo, PhD, Suzanne Kamel-Reid, PhD, John M. Goldman, MD, Jane F. Apperley, PhD, Jaspal S. Kaeda, PhD

Blood (2006) 108 (11): 2153.

https://doi.org/10.1182/blood.V108.11.2153.2153

Published: 2006

Journal Articles

Disordered Expression of HIPK Family Members in MDS and AML.

Chunhong Gu, MD, PhD, Helen J. Zheng, MSc, Lap Shu Chan, BSc, Joseph Brandwein, MD, Suzanne Kamel-Reid, PhD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Andre C. Schuh, MD, Richard A. Wells, MD, DPhil

Blood (2004) 104 (11): 4311.

https://doi.org/10.1182/blood.V104.11.4311.4311

Published: 2004

Journal Articles

EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis.

Christine V. Ichim, MSc, Mahadeo A. Sukhai, MSc, J. Brandwein, MD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Andre C. Schuh, MD, Suzanne Kamel-Reid, PhD, Norman N. Iscove, MD, PhD, Richard A. Wells, MD, DPhil

Blood (2004) 104 (11): 3226.

https://doi.org/10.1182/blood.V104.11.3226.3226

Published: 2004

NARROW

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Utility of Next Generation Sequencing in Prognostication and Therapeutic Decision Making in Cytogenetically Normal AML with DNMT3A Mutations

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy

Prospective Next-Generation Sequencing Molecular Profiling of Myeloid Malignancies: Assessment of Information Benefit and Impact on Patient Care

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Mixed Fields on RHD Typing As an Indicator of Malignancy-Associated Loss of Heterozygosity on Chromosome 1p in Myeloid Neoplasm

Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis

BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.

Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput Techniques

Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy.

Systems Analysis Reveals Regulators of Apoptosis, Cell Cycle, Signal Transduction and Transcription as Novel Direct Targets of the Acute Promyelocytic Leukemia Fusion Protein NuMA-RAR α

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

Disordered Expression of HIPK Family Members in MDS and AML.

EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only